UroGen Pharma (FRA:UR8) Moat Score: 5/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UR8 UroGen Pharma Ltd FRA:UR8
60 GF Score
Price €33.86
GF Value €18.16
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma Moat Score?

UroGen Pharma FRA:UR8 +2.89% 60 Moat Score is 5 as of Jul. 15, 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 60/100 and a GF Value™ of €18.16 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,396 Biotechnology companies, UroGen Pharma ranks better than 96.7% on this metric.

UroGen Pharma has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

UroGen Pharma has Narrow Moat: UroGen Pharma Ltd has a solid narrow moat due to its valuable intellectual property and patents in the pharmaceutical industry. The company benefits from regulatory barriers and some pricing power, but faces competition and lacks strong brand strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes UroGen Pharma might have Narrow Moat - Solid narrow moat.

UroGen Pharma  (FRA:UR8) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

UroGen Pharma Moat Score Related Terms

FRA:UR8 vs SEPN, FTRE, MLTX: Moat Score Comparison

For the Biotechnology subindustry, UroGen Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Moat Score falls into.


FRA:UR8
60GF Score
UroGen Pharma Ltd FRA:UR8
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
UroGen Pharma (FRA:UR8) has a Moat Score of 5 as of Jul. 15, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, UroGen Pharma ranks #46 out of 1396 companies in the Biotechnology industry, placing it in the top 3.3%.
Is UroGen Pharma's Moat Score too high?
UroGen Pharma's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. UroGen Pharma's value of 5 is 150% above this industry median. Based on the distribution chart, UroGen Pharma ranks #46 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UroGen Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Moat Score compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #46 out of 1396 companies for Moat Score. This places UroGen Pharma in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. UroGen Pharma's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €18.16, compared to a current price of €33.86 — trading 86.5% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. UroGen Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Moat Score is 5 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €33.86 is trading 86.5% above its estimated GF Value™ of €18.16. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • Moat Score: 5
  • GF Value™: €18.16 vs. price of €33.86 (86.5% above fair value)
  • GF Score™: 60/100 with 10 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1396)

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
60GF Score

Get the complete analysis for FRA:UR8

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.86
Price
€18.16
GF Value